

# George L Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5763179/publications.pdf>

Version: 2024-02-01

52  
papers

738  
citations

623734

14  
h-index

552781

26  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1415  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Optical Coherence Tomography for Quantifying Human Cutaneous Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 271.e1-271.e8.  | 1.2 | 2         |
| 2  | Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.  | 5.2 | 8         |
| 3  | Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021, 5, 4278-4284.  | 5.2 | 36        |
| 4  | Replicated Risk Index of Patient Functional Status Prior to Allogeneic Hematopoietic Cell Transplantation Predicts Healthcare Utilization and Survival. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 875.e1-875.e9.  | 1.2 | 1         |
| 5  | Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies. <i>Blood</i> , 2021, 138, 1791-1791. | 1.4 | 6         |
| 6  | Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients. <i>Blood</i> , 2021, 138, 4066-4066.   | 1.4 | 0         |
| 7  | Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , 2021, 138, 165-165.   | 1.4 | 6         |
| 8  | Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 77-85.  | 2.4 | 4         |
| 9  | Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 278-284.  | 2.0 | 10        |
| 10 | Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 772-777.  | 2.0 | 16        |
| 11 | Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell-Associated Encephalopathy (ICE) Score. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e271-e274.  | 2.0 | 13        |
| 12 | Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2147-2154.   | 2.0 | 4         |
| 13 | The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473.  | 2.0 | 4         |
| 14 | Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1869-1874.   | 2.0 | 1         |
| 15 | Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 689-698.   | 2.0 | 9         |
| 16 | Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 599-605.   | 2.0 | 20        |
| 17 | β2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogeneic Transplantation While Preserving Graft Versus Leukemia Effect. <i>Blood</i> , 2019, 134, 1915-1915.   | 1.4 | 3         |
| 18 | Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease. <i>Blood</i> , 2019, 134, 4516-4516.  | 1.4 | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Impact of conditioning regimen on peripheral blood hematopoietic cell transplant. <i>World Journal of Clinical Oncology</i> , 2019, 10, 86-97.   | 2.3 | 0         |
| 20 | Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1727-1732.  | 2.0 | 8         |
| 21 | BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 651-653.   | 2.4 | 2         |
| 22 | Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 373-380. | 2.0 | 15        |
| 23 | Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.  | 5.2 | 27        |
| 24 | Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. <i>Journal of Immunology</i> , 2017, 199, 336-347.   | 0.8 | 11        |
| 25 | T Cell-Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses. <i>Journal of Immunology</i> , 2017, 199, 3700-3710.  | 0.8 | 34        |
| 26 | Quantifying MHC dextramer-induced NFAT activation in antigen-specific T cells as a functional response parameter. <i>Methods</i> , 2017, 112, 75-83.   | 3.8 | 5         |
| 27 | Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.   | 1.4 | 43        |
| 28 | Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.  | 2.0 | 71        |
| 29 | Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.  | 2.0 | 113       |
| 30 | A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.  | 7.0 | 68        |
| 31 | Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3454-3454.               | 1.4 | 0         |
| 32 | Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2015, 195, 4514-4523.   | 0.8 | 21        |
| 33 | Housing Temperature-Induced Stress Is Suppressing Murine Graft-versus-Host Disease through $\beta_2$ -Adrenergic Receptor Signaling. <i>Journal of Immunology</i> , 2015, 195, 5045-5054.  | 0.8 | 48        |
| 34 | Effect of Immune Reconstitution on Survival after Autologous Hematopoietic Cell Transplant for B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3173-3173.   | 1.4 | 1         |
| 35 | Remestemcel-L for acute graft-versus-host disease therapy. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 261-269.  | 3.1 | 10        |
| 36 | Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1369-1374.  | 2.0 | 5         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples. , 2014, , n/a-n/a.   |     | 8         |
| 38 | Perforin Is Important For Both CD4+ and CD8+ T Cell-Mediated Graft-Versus-Tumor Effect But Plays Differential Roles In CD4+ and CD8+ T Cell Expansion After Allogeneic Transplantation. Blood, 2013, 122, 3255-3255.                              | 1.4 | 0         |
| 39 | Analysis Of Immune Cell Populations Before and After Autologous Hematopoietic Stem Cell Transplant For Multiple Myeloma: Association With Early Recovery Of Absolute Lymphocyte Count and Progression-Free Survival. Blood, 2013, 122, 3348-3348. | 1.4 | 0         |
| 40 | Short Course of Levofloxacin During Neutropenia Prevents Early and Late Bacteremia Episodes After Allogeneic Blood and Marrow Transplantation (alloBMT). Blood, 2012, 120, 4141-4141.   | 1.4 | 0         |
| 41 | A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood, 2011, 118, 4070-4078.  | 1.4 | 40        |
| 42 | Fludarabine, Melphalan and Low Dose Total Body Irradiation for Reduced Intensity Conditioning (RIC) Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT). Blood, 2011, 118, 4570-4570.  | 1.4 | 0         |
| 43 | Micro Dose Methotrexate (MTX) Is Equivalent to Full Dose MTX and Superior to No MTX for Acute Graft-Versus-Host Disease Prophylaxis. Blood, 2011, 118, 3038-3038.   | 1.4 | 0         |
| 44 | A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease. Blood, 2011, 118, 1986-1986.  | 1.4 | 0         |
| 45 | Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood, 2011, 118, 3096-3096.  | 1.4 | 4         |
| 46 | A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis.. Blood, 2009, 114, 3304-3304.   | 1.4 | 0         |
| 47 | Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses While Recipient Plasma Cells Persist.. Blood, 2008, 112, 2234-2234.   | 1.4 | 1         |
| 48 | IgG Allotypes Reveal That Antimicrobial Humoral Immunity Persists after Reduced-Intensity Hematopoietic Cell Transplantation. Blood, 2008, 112, 349-349.  | 1.4 | 3         |
| 49 | Identification of a Homeobox-Like Protein Immune Response in Bone Marrow Transplant Patients. Blood, 2008, 112, 4856-4856.  | 1.4 | 0         |
| 50 | Post Transplant Allogeneic Antibody Responses Form against Annexin 8. Blood, 2008, 112, 4605-4605.  | 1.4 | 0         |
| 51 | X-linked clonality testing: interpretation and limitations. Blood, 2007, 110, 1411-1419.  | 1.4 | 55        |
| 52 | Tlr4 Is Monoallelically Expressed in Human BFU-E and CFU-E and May Have Application as a Clonality Marker in Hematological Disorders Due to Somatic Mutations in Both Males and Females.. Blood, 2006, 108, 3619-3619.                            | 1.4 | 0         |